Therapeutic focus


A illustration of a plasma

Therapeutic focus » Our aim

Drug discovery targeting chronic pain

PHARMNOVO AIMS TO CREATE novel drugs with superior clinical properties to treat patients with chronic pain using our knowledge and experience of drug design and G protein-coupled receptor pharmacology. Our specific target is the delta opioid receptor (DOR).

PharmNovo’s aim is to target the multiple disease areas of chronic pain, including neuropathic, osteoarthritic and migraine pain and the commonly associated conditions of anxiety and depression. These disease areas have mechanistic commonalities susceptible to the company’s novel approach to drug discovery.

Given the complexity of chronic pain states we think it is impractical to attempt to produce a medicine that will treat all aspects of the various disorders and PharmNovo’s development strategy is focussed on sensory hypersensitivity conditions, such as mechanical allodynia and hyperalgesia, which are common and hard-to-treat components of many chronic pain states.

Although PharmNovo’s immediate focus is on the use of DOR activating drugs (agonists) in chronic pain therapy, other clinical opportunities exist including the treatment of neurological disorders such as migraine, Parkinson’s and Alzheimer’s Diseases and chronic cough.

Latest news

View all
December 22, 2022

PharmNovo at Biostock

CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.

Read more
December 22, 2022

Seasons Greetings 2022

The PharmNovo team would like to wish you a Merry Christmas and a Happy New Year!

Read more
October 11, 2022

Strengthening the team

PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager

Read more
September 20, 2022

Good press in SvD

Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.

Read more

By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Awesome 👌